<DOC>
	<DOCNO>NCT01946074</DOCNO>
	<brief_summary>This Phase 1/1b open-label study evaluate safety , pharmacokinetics ( PK ) , preliminary efficacy ABT-165 subject advance solid tumor . The early clinical development plan ABT-165 base activity demonstrate preclinical model .</brief_summary>
	<brief_title>Study ABT-165 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subject must advance solid tumor amenable surgical resection approve therapeutic option demonstrate clinical benefit . Subject adequate bone marrow , renal , hepatic coagulation function . Subject must measurable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) version 1.1 disease evaluable assessment tumor antigen include limited cancer antigen ( CA125 ) prostatespecific antigen ( PSA ) . Women childbearing potential must negative serum pregnancy test within 14 day prior initiation treatment . Female subject consider childbearing potential must document surgically sterile postmenopausal least 1 year . Women childbearing potential men must agree use adequate contraception . Subjects combination therapy cohort must meet inclusion criterion eligible receive paclitaxel FOLFIRI per current prescribing information , discretion Investigator . Subject receive anticancer therapy include chemotherapy , radiation therapy , immunotherapy , biologic , investigational therapy within period 21 day anticancer herbal therapy within 7 day prior Cycle 1 Day 1 ABT165 . Subject uncontrolled metastasis central nervous system ( CNS ) . Subject unresolved clinically significant toxicity prior anticancer therapy , define Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 high . Subject history ( within previous 5 year ) clinically significant pulmonary hypertension , uncontrolled systemic hypertension , hypertensive crisis , congestive heart failure , myocardial infarction , aneurysm aneurysm repair leave ventricular ejection fraction ( LVEF ) less equal 50 % . Subjects enrol combination therapy phase must meet exclusion criterion must eligible receive paclitaxel FOLFIRI per current prescribing information , discretion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>cancer</keyword>
	<keyword>neoplasm</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>